ketamine

PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome

Shots: The US FDA has granted ODD to the Ketamine for the treatment of complex regional pain syndrome (CRPS) which is a rare chronic pain and inflammatory condition following an injury to a limb The ODD follows the US FDA’s ODD of ketamine for the treatment of ALS, granted on Aug 04, 2021 Ketamine acts …

PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome Read More »

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

Shots: The company initiates P-II KET-LID clinical trial to evaluate the safety, efficacy, and PK of Ketamine (sub-anesthetic, IV) vs PBO in patients with LID associated with PD. The patient enrollment is expected to initiate in Oct’21 with an anticipated PDUFA date on Q4’21 The 1EPs & 2EPs are the changes in the total score …

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease Read More »

VC fund dedicated to psychedelic meds launches in UK

In the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – magic or otherwise – and venture capital money is starting to follow. Today sees the launch of the first investment fund in the UK devoted to psychedelic healthcare, with plans to invest in “revolutionary mind-altering medicines to …

VC fund dedicated to psychedelic meds launches in UK Read More »